ADVA
12.5.2020 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it is playing a key role in a unique research initiative extending post-quantum security to VPN networks. Leveraging the ADVA FSP 150 with ConnectGuard™ Ethernet encryption, the Quantum-Secure VPN Modules and Operation Modes (QuaSiModO) project is testing new quantum-resistant algorithms in the packet domain. It will develop viable security solutions that can protect Layer 2 and 3 data against all forms of cyberattack, including those from quantum computers. By participating in the initiative, ADVA is extending its industry-leading work with quantum-safe cryptography in optical transport to higher network layers. Other QuaSiModO project partners are the Fraunhofer Institute of Applied and Integrated Security, the Ludwig Maximilian University of Munich and genua GmbH.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200512005043/en/
“As part of the QuaSiModO project, we’re continuing to drive innovation in future-proof cryptography. This initiative extends comprehensive post-quantum security to VPNs and enables businesses and government institutions to protect their data from tomorrow’s attacks,” said Jörg-Peter Elbers, SVP, advanced technology, ADVA. “Together with our partners, we’re ensuring that network security technology doesn’t fall behind in the computing power race. Our role in the project combines our experience with transport layer post-quantum security and our proven expertise when it comes to encrypting Carrier Ethernet connectivity. We’re helping to create a solution able to protect packet services today and ready to be upgraded later to comply with emerging specifications from standards bodies such as the USA’s National Institute of Standards and Technology.”
Quantum computers of sufficient size and reliability could arrive within the next 10 to 15 years. This may mean that today’s widely applied data protection technologies will no longer be sufficient. What’s more, sensitive and valuable information may be at risk right now from harvesting attacks, with attackers storing information today to decrypt it as soon as large quantum computers are available. Funded by the German Federal Ministry of Education and Research, the QuaSiModO project is researching, testing and helping to standardize quantum-resistant algorithms in VPN implementations. It aims to extend existing IPSec and MACsec communication protocols with quantum-resistant procedures and support the development of complete solutions. The initiative is utilizing ADVA FSP 150 edge devices with ConnectGuard™ Ethernet encryption technology based on an enhanced version of MACsec. The solution provides high throughput and low-latency performance as it encrypts across multiple domains and service provider networks.
“When quantum computers emerge, they’ll be able to quickly crack complex problems that would take today’s most powerful supercomputers many years to solve. That’s why enterprises, governments and communication service providers are looking to leverage security technology built on quantum-safe algorithms,” commented Alexander von Gernler, head of research, genua GmbH. “For a decade, we’ve been focused on the threat posed by large quantum computers, and much of our work in recent years has been about developing practical quantum-resistant signatures and key establishment protocols. Now, we’re leading the QuaSiModO consortium, working with ADVA and the other partners to bring post-quantum security to network Layers 2 and 3, and deliver the robust future-proof protection that classical encryption technologies simply can’t.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005043/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
